Kimber Ian, Dearman R J, Basketter D A, Ryan C A, Gerberick G F
Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire, UK.
Contact Dermatitis. 2002 Dec;47(6):315-28. doi: 10.1034/j.1600-0536.2002.470601.x.
The local lymph node assay (LLNA) was developed originally as a method for the identification of chemicals that have the potential to cause skin sensitization and allergic contact dermatitis. The assay is based on an understanding that the acquisition of contact sensitization is associated with, and dependent upon, the stimulation by chemical allergens of lymphocyte proliferative responses in skin-draining lymph nodes. Those chemicals that provoke a defined level of lymph node cell (LNC) proliferation (a 3-fold or greater increase compared with concurrent vehicle controls) are classified as skin sensitizers. Following its original inception and development, the LLNA was the subject of both national and international interlaboratory collaborative trials, and of very detailed comparisons with other test methods and with human skin sensitization data. The assay has now been validated fully as a stand-alone test for the purposes of hazard identification. In recent years, there has been a growing interest also in the use of the LLNA to assess the potency of contact allergens and in risk assessment. There is reason to believe that the extent of skin sensitization achieved is associated with the vigour of LNC proliferation induced in draining nodes. Given this relationship, the relative potency of skin sensitizing chemicals is measured in the LLNA by derivation of an EC3 value, this being the concentration of chemical required to provoke a 3-fold increase in the proliferation of LNC compared with controls. Experience to date indicates that relative potency as determined using this approach correlates closely with what is known of the activity of skin sensitizing chemicals in humans. In this article, we review the development, evaluation and validation of the LLNA for the purposes of hazard identification, and the more recent application of the method for evaluation of potency in the context of risk assessment. In addition, we consider what new applications and modifications are currently being investigated.
局部淋巴结试验(LLNA)最初是作为一种识别具有引起皮肤致敏和过敏性接触性皮炎潜力的化学物质的方法而开发的。该试验基于这样一种认识,即接触致敏的获得与皮肤引流淋巴结中淋巴细胞增殖反应受到化学变应原的刺激有关,并依赖于此。那些引起一定水平的淋巴结细胞(LNC)增殖(与同时进行的赋形剂对照相比增加3倍或更多)的化学物质被归类为皮肤致敏剂。自最初创立和发展以来,LLNA一直是国家和国际实验室间协作试验的主题,并且与其他测试方法以及人类皮肤致敏数据进行了非常详细的比较。该试验现已被充分验证为一种用于危害识别的独立测试。近年来,人们对使用LLNA评估接触性变应原的效力以及进行风险评估也越来越感兴趣。有理由相信,所实现的皮肤致敏程度与引流淋巴结中诱导的LNC增殖活力有关。鉴于这种关系,在LLNA中通过推导EC3值来测量皮肤致敏化学物质的相对效力,EC3值是与对照相比引起LNC增殖增加3倍所需的化学物质浓度。迄今为止的经验表明,使用这种方法确定的相对效力与已知的人类皮肤致敏化学物质的活性密切相关。在本文中,我们回顾了用于危害识别的LLNA的开发、评估和验证,以及该方法在风险评估背景下评估效力的最新应用。此外,我们考虑了目前正在研究的新应用和改进。